Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)
Author
Mundle, S.
Li, S.
Luna, Y.
Chi, K.
Ozguroglu, M.
Woo, H.
Fizaz, K.
Sulur, G.
Tran, N.
Fein, L.
Matsubara, N.
Rodriguez-Antolin, A.
Alekseev, B.
Ye, D.
Feyerabend, S.
Protheroe, A.
Metadata
Show full item recordCollections
- Bildiri [64839]